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Making sense of the sensor: 
Mysteries of the macula densa
RC Blantz1
Increases in luminal NaCl concentration at the macula densa (MD), 
the sensing element, activate tubuloglomerular feedback (TGF). MD 
cell volume increases when increments are isosmotic and shrinks if 
osmolality increases. This interesting finding introduces additional 
complexity to the role of the MD in TGF.
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At first glance the article by Komlosi 
and colleagues1 (this issue) may appear 
a study in parochial basic science focus-
ing on tubular luminal factors that reg-
ulate the cell volume of a peculiar cell, 
the macula densa (MD), located in the 
distal nephron. Th is would be wrong. 
For several historical, physiologic, and 
clinically relevant reasons, the infor-
mation is important and a necessary 
step in progress to our understanding 
of the role of the kidney in maintain-
ing NaCl and volume homeostasis. It is 
now accepted that the tubuloglomerular 
feedback (TGF) system plays a legitimate 
physiologic role in maintaining stability 
of kidney function by (1) sustaining a 
relationship between tubular reabsorp-
tion and the fi ltered load or glomerular 
fi ltration rate (GFR), (2) contributing 
signifi cantly to the effi  ciency of autoreg-
ulation of kidney blood fl ow and GFR, 
and (3) providing a system that can tem-
porally adapt or reset to newly imposed 
physiologic circumstance.2 Th e sensing 
limb of this cybernetic system is housed 
within MD cells that are connected via 
extraglomerular mesangial cells to the 
glomerular aff erent arteriole and glomer-
ulus to constitute the juxtaglomerular 
apparatus.3 It is therefore important to 
defi ne the boundary conditions of how 
changes in solute and NaCl delivery 
aff ect the transport and sensing func-
tions of the MD. Komlosi et al.1 defi ne 
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important aspects of how luminal NaCl 
concentration and osmotic pressure sep-
arately infl uence the sensor (Figure 1), a 
cell with attributes diff erent from those 
of adjacent thick ascending limb cells. 
Debates on the nature of the aff erent 
signaling mechanisms of TGF date back 
several decades and represent interesting 
history in scientifi c investigation. Major 
physiologists in the mid-1960s, includ-
ing Arthur Guyton and Klaus Th urau, 
espoused hypotheses regarding a TGF 
system.4,5 Guyton and colleagues pro-
posed that changes in flow to the MD 
would produce changes in renal blood 
flow by sensing osmolality and solute 
delivery, not just NaCl.4 Thurau and 
Schnermann argued that luminal NaCl 
concentration and NaCl reabsorption 
constituted the signal at the MD.5 Schner-
mann, Wright, and co-workers soon 
thereaft er supplied the fi rst objective data 
on which to base conclusions on the role 
of osmolality versus NaCl as the MD sig-
nal of TGF.6,7 In nephron microperfusion 
studies, increasing late proximal flow 
with NaCl/HCO3 solutions from normal 
to elevated values reduced nephron GFR 
by approximately 10 nl/min. However, 
solutions containing isotonic mannitol 
or mannitol and Na2SO4 produced no 
TGF response. Blantz and Konnen soon 
thereafter demonstrated that isotonic 
addition of solutes such as glucose and 
amino acids to perfusion fl uids (5 mM, 
respectively) produced approximately 
60% reductions in the magnitude of TGF 
responses.8 Addition of non-electrolyte 
solutes did not alter the rise in chloride 
concentration in distal tubular fl uid nor 
the osmolality but was associated with 
an approximately 20% reduction in chlo-
ride reabsorption between late proximal 
and early distal tubules, suggesting a 
reduction in chloride transport, possibly 
including the MD. 
Th e study by Komlosi et al.1 deline-
ates the separate eff ects of luminal NaCl 
concentration and luminal osmolality 
by examining parallel changes in MD 
cell volume. An increase in MD lumi-
nal NaCl at constant luminal osmolality 
caused a reversible signifi cant increase in 
MD cell volume (Figure 1). Concurrent 
application of furosemide eliminated 
83% of this cell swelling, suggesting that 
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enhanced NaCl transport into the MD 
via the Na+-K+-2Cl– cotransporter gen-
erated this eff ect. Intracellular Na will 
rise to higher levels, causing water to 
move into the cell. However, the eff ects 
of increased luminal osmolality, regard-
less of solute type, clearly override the 
effect of NaCl uptake on changes in 
MD cell volume. Komlosi et al.1 clearly 
demonstrate that increases in luminal 
osmolality, even if generated by lumi-
nal NaCl, produce cell shrinkage and 
loss of water from the cell. What role do 
changes in MD cell volume play in TGF 
function? Komlosi and colleagues1 eval-
uated the eff ects of isosmolar urea, the 
major endogenous solute, versus NaCl 
on changes in MD cell volume. Changes 
in cell volume were substantially greater 
with NaCl, suggesting that the refl ection 
coeffi  cient of the MD apical membrane 
for NaCl is greater than that for urea. 
Th e transport eff ects of increased lumi-
nal Na are counteracted by the luminal 
Na contribution to osmolality, making 
the specifi c eff ects on cell volume highly 
complex. MD cell volume changes may 
modify elements of TGF other than 
aff erent arteriolar diameter responses. 
Th e basic questions are: (1) how does 
the MD cell volume change, and across 
which membrane is water moving; and 
(2) does MD cell shrinkage in response 
to increased luminal osmolality play a 
specifi c role in sensing of the MD TGF 
signal? Sufficient data exist to permit 
conclusions on the fi rst of these queries. 
Apical hydraulic conductivity of the cor-
tical thick ascending limb (cTAL) is low 
to negligible and much lower than that 
of the MD cell apical membrane. Baso-
lateral hydraulic conductivity of the MD 
cell and cTAL cell is signifi cantly higher 
than that of the apical membrane.3 Both 
the MD and the cTAL swell with selec-
tive isosmotic increases in luminal NaCl, 
suggesting that water movement occurs 
across the basolateral membrane in both 
cell types. However, when luminal osmo-
lality is increased, with the use of either 
NaCl or other solutes, only the MD cell 
shrinks, implying water movement from 
the MD cell into the lumen in response 
to increased luminal tonicity (Figure 1). 
cTAL cells never shrink but only swell 
with increasing luminal NaCl and osmo-
lality, refl ecting basolateral fl uid uptake. 
Figure 3b in the article by Komlosi et al.1 
dramatically demonstrates the opposite 
directional changes in cTAL and MD 
cell volumes when luminal tonicity is 
enhanced by an increase in NaCl content. 
Th e second question, of the consequences 
to TGF signaling of MD cell shrinkage, 
remains unanswered by the available 
data. Adenosine triphosphate release 
and prostaglandin E2 release are logical 
consequences of cell-volume changes,3 
but increased cell volume would be a 
more logical cause than reductions in 
cell volume. Th e absence of cell-volume 
regulation of the MD cell could make this 
mechanism highly complex. 
How can we apply these in vitro assess-
ments to the unresolved issues relating 
to observations in vivo at the single-
nephron and whole-kidney levels? Th e 
‘physiologic’ changes in MD luminal 
NaCl across which TGF exerts its major 
infl uences have been defi ned in two stud-
ies from our laboratory using Munich-
Wistar-Frömter rats with early distal 
tubules near the MD on the kidney sur-
face. With increments in late proximal 
fl ow rate of 5–8 nl/min, major reductions 
in single nephron GFR (SNGFR) were 
observed encompassing approximately 
60%–70% of the maximal TGF response, 
and across this range early-distal tubular 
Na increased from 18–23 mM at normal 
flows to 29–35 mM during increased 
delivery and TGF activation.9,10 Paral-
lel values for luminal chloride increased 
from 16 to 23 mM. In the study by Kom-
losi et al.,1 increases in NaCl from 20 to 
40 mM and in luminal osmolality from 
98 to 135 mOsm caused cell shrinkage 
and not swelling. Prior publications 
from this group showed only cell swell-
ing when both NaCl (25 to 135 mM) and 
osmolality (210 to 300 mOsm/kg) were 
increased.11 Measurements of changes 
in luminal osmolality in vivo are impor-
tant to our understanding of these proc-
esses and the independent infl uence of 
cell volume, as the TGF-induced SNGFR 
responses across these changes in NaCl 
are substantial.
It is logical that replacement of NaCl with 
isotonic mannitol completely prevents TGF 
Figure 1 | Proposed effects of increased macula densa flow rate and corresponding 
sodium chloride (NaCl) luminal concentration on macula densa cell volume. Under isosmotic 
conditions (upper panel), increased NaCl concentration in the lumen is associated with significant 
cell swelling, presumably via water entry from the basolateral aspect of the macula densa (MD) cell. 
With increases in both luminal osmolality and NaCl, the MD cell will decrease in volume, primarily 
as a result of water removal across the apical membrane. The exact physiologic effects of these 
changes in cell volume on the TGF signal have not been defined.
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responses in vivo, because mannitol inhib-
its NaCl transport in the loop of Henle and 
the MD cell.6 It is harder to understand the 
major negative impact of isotonic glucose 
and amino acids (5 and 5 mM, respec-
tively) in late proximal perfusion, which 
inhibited 60% of the TGF response in vivo.8 
This effect was associated with a major 
reduction in loop of Henle chloride trans-
port. Th ese molecules may express refl ec-
tion coeffi  cients of 1.0 for the MD, higher 
than for the NaCl, and are not actively 
transported by the MD cell. Luminal NaCl 
concentrations and osmolality near the 
MD were not diff erent. Th ese results may 
relate to the fi ndings that hyperglycemia 
and experimental diabetes are conditions 
associated with modest but significant 
reductions in TGF activity. Studies are 
required to quantify and fully characterize 
the aff erent arteriolar and TGF responses 
to specifi c changes in (1) luminal NaCl, 
(2) luminal osmolality, and (3) the identity 
of the specifi c solutes contributing to the 
luminal osmotic pressure and changes in 
MD cell volume. 
Komlosi and co-workers1 have now 
provided valuable boundary conditions 
on the eff ects of increased luminal NaCl 
and luminal osmolality on MD cell vol-
ume. Further studies are required on the 
specifi c role of decreased MD cell vol-
ume in the magnitude, direction, and 
character of the TGF sensor. Combined 
in vivo and in vitro assessments within 
the relevant range of changes in lumi-
nal NaCl and osmolality will help us to 
understand the operation of this com-
plex and important regulatory system. 
Th e article by Komlosi and co-workers1 
represents an excellent fi rst step in this 
direction. Th erefore, their study is not 
basic and parochial in nature. It is basic 
and highly relevant to physiology and 
even clinical nephrology if one under-
stands the issues. 
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Revascularization in 
atherosclerotic renovascular 
disease: Problems beyond the 
obstruction
AR Chade1
The main goal in the treatment of obstructive atherosclerotic 
renovascular disease (ARVD) is to preserve or recover renal function. 
The ARVD kidney continues to deteriorate in 20–40% of cases despite 
restoration of blood flow. Holden et al. report that renal function 
stabilized or improved in up to 97% of patients with the use of a distal 
embolic protection device.
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The patient population with end-stage 
renal disease has been growing at a rate of 
8%–14% per year for the past two decades.1 
In almost one-third of those cases, athero-
sclerotic renovascular disease (ARVD) has 
been the cause of end-stage renal disease. 
Atherosclerotic lesions account for more 
than 90% of cases of renal artery lesions 
and are the cause of end-stage renal dis-
ease in up to 27% of patients over 45 years 
of age at the start of dialysis. 
The main goal in the treatment of 
obstructive ARVD is to recover or pre-
serve renal function. Underlining this 
concept is the notion that ARVD is a 
progressive disorder. Major advances 
in revascularization techniques have 
emerged during the past 20 years. Per-
cutaneous transluminal renal angioplasty 
(PTRA) and stenting have become the 
common treatments for patients with 
clinically signifi cant renal artery stenosis 
and reversible renal disease. PTRA has a 
high success rate, long-term patency, and 
a low complication rate. Nevertheless, 
these treatments oft en fail to improve 
blood pressure or renal function despite 
successful renal revascularization. Post-
PTRA deterioration of renal function 
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